The definitive directory of companies using artificial intelligence to accelerate drug discovery, molecule design, and clinical development. Curated for biotech operators, investors, and BD teams.
End-to-end AI drug discovery platform combining automated wet labs with machine learning phenotypic screening. Following the Exscientia merger, operates one of the largest integrated discovery platforms in the industry.
Generative AI pioneer with Pharma.AI platform spanning target identification, molecule design, and clinical outcome prediction. ISM001-055 achieved positive Phase IIa results in idiopathic pulmonary fibrosis.
Physics-based computational platform combining quantum mechanics and machine learning for molecular design. Nimbus-originated TYK2 inhibitor zasocitinib (TAK-279) advanced into Phase III trials.
Motion-based drug design platform using computational simulations of protein dynamics. Pipeline addresses breast cancer, vascular malformations, solid tumors, and Fabry disease.
Structure-based AI modeling with AtomNet deep learning platform. Screens billions of compounds against disease targets. Active collaborations with 250+ research institutions.
Chemistry-first, AI-native small molecule platform (EMMI). Discovery partnerships with Calico, Bristol Myers Squibb, and Gilead. Internal pipeline focused on immunology.
Generative AI drug creation platform combining synthetic biology with deep learning for de novo antibody design. Validates novel biologic drug candidates from scratch.
Quantum chemistry meets AI at industrial scale. Digital twin simulations predict molecular properties. Cloud-native infrastructure for physics-based small molecule design.
Featured companies get full profiles with logos, descriptions, pipeline data, and backlinks visible to 86,757 biotech professionals. Become a data partner to stand out.
The featured companies above have full profiles, backlinks, and priority placement. The rest are names in a database. Learn how to upgrade your presence.
The BioMed Nexus AI Drug Discovery Companies Directory is the most comprehensive listing of companies using artificial intelligence, machine learning, and computational methods to accelerate drug discovery and development. Updated regularly by our editorial team, this directory covers generative chemistry platforms, phenomics-based screening companies, computational biology firms, protein design startups, clinical AI tools, and drug repurposing specialists.
Whether you are a biotech executive evaluating partnership opportunities, an investor screening the AI drug discovery landscape, or a BD professional sourcing platform capabilities, this directory provides the structured data and company profiles you need to make informed decisions.
Companies can claim their free basic listing or upgrade to an Enhanced Profile or Full Landing Page for priority placement, backlinks, and permanent indexing on the BioMed Nexus domain. Contact our partnerships team to discuss listing options.
